文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

通过国家质量保证项目改善前列腺癌放疗结局:英国大型学术中心结果

Driving Improvement in Prostate Cancer Radiation Therapy Outcomes Through a National Quality Assurance Program: Results From a Large Academic Center in the United Kingdom.
PubMed 文献 · Pract Radiat Oncol · 2026-09-19

英国国家前列腺癌审计(NPCA)报告某机构2016年根治性EBRT后重度晚期GI毒性为16%,高于全国平均10%。该研究回顾性验证毒性并行多学科根因分析,发现直肠平均剂量较高与毒性相关,2020-2021年方案调整后2022年审计毒性降至7.5%。

要点

  • NPCA报告的本中心2016年重度晚期GI毒性为16%,全国平均为10%。
  • 直肠平均剂量>45 Gy(37次)或>35 Gy(20次)与重度晚期GI毒性显著相关(P=.043)。
  • 方案调整后2022年NPCA报告重度晚期GI毒性降至7.5%。

核心结论

  • NPCA报告触发多学科EBRT路径优化,随后GI毒性大幅下降,体现国家审计项目改善放疗结局的价值。

研究设计与样本

  • 回顾性分析2016年在本中心接受根治性EBRT的全部前列腺癌患者,随访数据可获取281/290例(96.8%)。
  • 重度晚期GI毒性定义为RTOG grade≥2毒性或放疗后2年内需结肠镜干预。
  • 对NPCA识别病例用临床和内镜记录独立验证,并行多学科根因分析,比较病例与对照队列。
  • 采用χ2、Mann-Whitney和t检验,P<.05为统计学显著。

主要发现

  • 2016年队列重度晚期GI毒性确认为16%。
  • 与患者或肿瘤特征、分割方案、CTV-PTV margin无显著关联。
  • 直肠平均剂量>45 Gy(37次)或>35 Gy(20次)与重度晚期GI毒性显著相关(P=.043)。
  • 重度晚期GI毒性患者中36%直肠直径≥4.5 cm。
  • 3例毒性最高患者中13%分次的摆位偏差可能可纠正。

关键数值与推荐

  • 重度晚期GI毒性定义:RTOG grade≥2或放疗后2年内需结肠镜干预。
  • 直肠平均剂量阈值:>45 Gy(37次)或>35 Gy(20次)与毒性显著相关(P=.043)。
  • 方案调整包括更严格直肠约束、灌肠使用、更新验证路径和减小CTV-PTV margin。
  • 2022年NPCA再审计报告重度晚期GI毒性降至7.5%。

临床怎么用

  • 将直肠平均剂量作为前列腺癌EBRT计划优化重点,参考>45 Gy(37次)或>35 Gy(20次)阈值。
  • 结合直肠直径(≥4.5 cm)和摆位验证偏差识别高危患者并干预。
  • 采用更严格直肠约束、灌肠、更新验证路径和减小CTV-PTV margin等综合措施降低GI毒性。

局限性

  • 单中心回顾性分析,样本来自2016年队列且随访数据可获取281/290例(96.8%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: National Prostate Cancer Audit (NPCA) is a national quality assurance program reporting prostate cancer outcomes across public sector hospitals in the United Kingdom. In 2019, the NPCA reported a 16% rate of severe late gastrointestinal (GI) toxicity following external beam radiation therapy (EBRT) at our institution from 2016, exceeding the national average of 10%. This prompted a systematic multidisciplinary review of the EBRT process to validate reported toxicity, identify modifiable contributors across the radiation therapy pathway, and assess the impact of subsequent protocol changes. METHODS AND MATERIALS: All patients with prostate cancer receiving radical EBRT at our center in 2016 were retrospectively reviewed. Severe late GI toxicity was defined as Radiation Therapy Oncology Group grade ≥2 toxicity or needing a colonoscopy with intervention within 2 years of radiation therapy. NPCA-identified cases were independently validated using clinical and endoscopy records. Multidisciplinary root cause analysis was performed, incorporating patient, tumor, treatment, dosimetric, rectal anatomy, and treatment verification imaging data. Patients with severe late GI toxicity were compared with a control cohort. The findings informed protocol changes implemented in 2020 to 2021, the impact of which was evaluated by the subsequent NPCA reaudit in 2022. χ2, Mann-Whitney, and t tests were used. P <.05 was considered statistically significant. RESULTS: Follow-up data were available for 281 of 290 (96.8%) patients in the 2016 cohort. Severe late GI toxicity was confirmed in 16%. There were no significant associations with patient or tumor characteristics, fractionation, or clinical target volume (CTV)-planning target volume (PTV) margins. Higher rectal mean dose (>45 Gy in 37 fractions or >35 Gy in 20 fractions) was significantly associated with severe late GI toxicity (P = .043). Of the patients with severe late GI toxicity, 36% had rectal diameters ≥4.5 cm. We identified potentially correctable setup deviations in 13% of fractions for 3 patients with the highest toxicity. Following protocol changes-tighter rectal constraints, enema use, updated verification pathway, and reduced CTV-PTV margins-the NPCA reported a reduction in severe late GI toxicity to 7.5% in patients treated in 2022. CONCLUSIONS: The NPCA reporting triggered multidisciplinary EBRT pathway optimization, which was followed by a substantial reduction in GI toxicity, highlighting the value of national audit programs in improving radiation therapy outcomes.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Manik V, Doss G, Ntentas G, et al. Driving Improvement in Prostate Cancer Radiation Therapy Outcomes Through a National Quality Assurance Program: Results From a Large Academic Center in the United Kingdom. Pract Radiat Oncol. 2026. PMID: 42762850. doi:10.1016/j.prro.2026.09.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。